Masaharu Tamaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Masaharu Tamaki has a total of 195 co-authors. Here are the top co-authors by number of shared publications:
- Hideki Nakasone
Division of Hematology Jichi Medical University Saitama Medical Center Saitama Japan
15 shared publications - Yoshinobu Kanda
Division of Hematology Jichi Medical University Saitama Medical Center Saitama Japan
13 shared publications - Shun-Ichi Kimura
Division of Hematology Jichi Medical University Saitama Medical Center Saitama Japan
12 shared publications Masakatsu Kawamura
Division of Hematology Jichi Medical University Saitama Medical Center Saitama Japan
11 shared publicationsAki Tanihara
Division of Hematology Jichi Medical University Saitama Medical Center Saitama Japan
10 shared publications- Yu Akahoshi
Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan
10 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by American Society of Hematology in Blood Advances
Adverse impact of deletion of the chromosome 6 on clinical outcomes after allogeneic hematopoietic transplantation
Graft-versus-leukemia (GVL) effect is mainly mediated by alloreactive T and NK cells through human leukocyte antigen (HLA). Although most HLA genes are located on the short arm of chromosome 6, the clinical significance of deletion of the short arm of chromosome 6 (del6p) which could attenuate the GVL effect has not been elucidated. We investigated impact of del6p at the diagnosis of hematological malignancies on allogeneic cell transplantation, using a Japanese registry database. Del6p was highly associated with additional chromosomal abnormalities. In the univariate analysis, the del6p group showed a higher incidence of relapse at 2 years among the entire cohort (2y-relapse 48.3% vs 25.7%, P <0.001). Multivariate analysis confirmed that del6p was significantly associated with an increased risk of relapse (HR 1.30 [95% CI: 1.02-1.65], P = 0.036). The del6p group also tended to be associated with relapse, when focusing on patients with complex karyotype (HR 1.25 [95% CI: 0.97-1.60], P = 0.079). Additionally, the impact of del6p on relapse was more evident in the HLA-mismatched than in the HLA-matched cohort. These results suggest that del6p at diagnosis might attenuate the GVL effect through HLA status.
- 23 October 2026
- Published by American Society of Hematology in Blood Advances
Open AccessAdverse impact of deletion of the chromosome 6 on clinical outcomes after allogeneic hematopoietic transplantation
Graft-versus-leukemia (GVL) effect is mainly mediated by alloreactive T and NK cells through human leukocyte antigen (HLA). Although most HLA genes are located on the short arm of chromosome 6, the clinical significance of deletion of the short arm of chromosome 6 (del6p) which could attenuate the GVL effect has not been elucidated. We investigated impact of del6p at the diagnosis of hematological malignancies on allogeneic cell transplantation, using a Japanese registry database. Del6p was highly associated with additional chromosomal abnormalities. In the univariate analysis, the del6p group showed a higher incidence of relapse at 2 years among the entire cohort (2y-relapse 48.3% vs 25.7%, P <0.001). Multivariate analysis confirmed that del6p was significantly associated with an increased risk of relapse (HR 1.30 [95% CI: 1.02-1.65], P = 0.036). The del6p group also tended to be associated with relapse, when focusing on patients with complex karyotype (HR 1.25 [95% CI: 0.97-1.60], P = 0.079). Additionally, the impact of del6p on relapse was more evident in the HLA-mismatched than in the HLA-matched cohort. These results suggest that del6p at diagnosis might attenuate the GVL effect through HLA status.
- 15 October 2026
- Published by Wiley in British Journal of Haematology
Repertoire diversity and dynamics of peripheral Th17 after allogeneic haematopoietic stem cell transplantation
Summary: Th17, a subset of helper T cells that produce interleukin‐17 (IL‐17), is thought to play a pivotal role in the pathogenesis of chronic graft‐versus‐host disease (GVHD). However, the kinetics of Th17 following allogeneic haematopoietic stem cell transplantation (allo‐HSCT) have not been elucidated. In this study, we evaluated the temporal dynamics and diversity of peripherally circulating Th17 after allo‐HSCT. The study included 86 patients who survived without disease relapse for 1 year or more, and for whom peripheral blood samples 3 months after allo‐HSCT were available. Th17 was detected and sorted by flow cytometry, and T‐cell receptor (TCR) repertoire was analysed by a next‐generation sequencing (NGS) method. Patients with chronic GVHD showed a higher TCR repertoire diversity, while those with severe chronic GVHD showed a lower TCR diversity and Th17/Cluster of Differentiation (CD) 4 ratio. The amino acid sequence in complementarity determining region 3 of Th17‐TCR was not apparently different between patients with and without chronic GVHD. Additionally, a higher Th17/CD4 ratio at 3 months was related to a lower incidence of subsequent chronic GVHD. The current study explored the kinetics of peripherally circulating Th17 after allo‐HSCT, which might be associated with the development of chronic GVHD.
- 15 October 2026
- Published by Wiley in British Journal of Haematology
Repertoire diversity and dynamics of peripheral Th17 after allogeneic haematopoietic stem cell transplantation
Summary: Th17, a subset of helper T cells that produce interleukin‐17 (IL‐17), is thought to play a pivotal role in the pathogenesis of chronic graft‐versus‐host disease (GVHD). However, the kinetics of Th17 following allogeneic haematopoietic stem cell transplantation (allo‐HSCT) have not been elucidated. In this study, we evaluated the temporal dynamics and diversity of peripherally circulating Th17 after allo‐HSCT. The study included 86 patients who survived without disease relapse for 1 year or more, and for whom peripheral blood samples 3 months after allo‐HSCT were available. Th17 was detected and sorted by flow cytometry, and T‐cell receptor (TCR) repertoire was analysed by a next‐generation sequencing (NGS) method. Patients with chronic GVHD showed a higher TCR repertoire diversity, while those with severe chronic GVHD showed a lower TCR diversity and Th17/Cluster of Differentiation (CD) 4 ratio. The amino acid sequence in complementarity determining region 3 of Th17‐TCR was not apparently different between patients with and without chronic GVHD. Additionally, a higher Th17/CD4 ratio at 3 months was related to a lower incidence of subsequent chronic GVHD. The current study explored the kinetics of peripherally circulating Th17 after allo‐HSCT, which might be associated with the development of chronic GVHD.
- 12 October 2026
- Published by Wiley in Transplant Infectious Disease
- p. e70337
A Novel Indicator of Cytomegalovirus Infection After Allogeneic Hematopoietic Cell Transplantation: Current CMV Reactivation
Background: Cytomegalovirus reactivation (CMVR) after allogeneic hematopoietic cell transplantation (allo‐HCT) is a reversible event, and conventional indicators such as the simple cumulative incidence cannot reflect transitional CMVR states. We propose a novel indicator, current CMVR (cCMVR), which visualizes both the occurrence and remission of CMVR over time. Methods: To evaluate the utility of cCMVR, we analyzed 389 CMV seropositive patients who had received their first allo‐HCT. cCMVR was defined as the probability of the state where anti‐CMV drugs were administered for CMVR or CMV disease without relapse or death at any time. Results: We compared two groups with or without letermovir prophylaxis (LTV and no‐LTV groups). The 1‐, 2‐, 3‐, and 6‐month cCMVR values were 0.0%, 0.0%, 2.9%, and 2.9% in the LTV group, and 7.1%, 31.9%, 11.0%, and 0.8% in the no‐LTV group. In the LTV group, cCMVR never exceeded 10%, while in the no‐LTV group, cCMVR peaked at approximately 2 months after allo‐HCT, and fewer than 5% of patients developed CMVR after 4 months post‐HCT. Next, in the no‐LTV group, we assessed cCMVR stratified according to the presence of risk factors for the simple cumulative incidence of CMVR, and this revealed that patients grafted from HLA‐mismatched related donors and those who received alemtuzumab for GVHD prophylaxis appeared to experience repeated episodes of CMVR, whereas the early difference in cCMVR according to pretransplant CMV‐IgG titer diminished over time. Conclusion: cCMVR could be a valuable indicator for visualizing recurrent CMV infection and illustrating differences in the time course of CMVR.
- 12 October 2026
- Published by Wiley in Transplant Infectious Disease
- p. e70337
A Novel Indicator of Cytomegalovirus Infection After Allogeneic Hematopoietic Cell Transplantation: Current CMV Reactivation
Background: Cytomegalovirus reactivation (CMVR) after allogeneic hematopoietic cell transplantation (allo‐HCT) is a reversible event, and conventional indicators such as the simple cumulative incidence cannot reflect transitional CMVR states. We propose a novel indicator, current CMVR (cCMVR), which visualizes both the occurrence and remission of CMVR over time. Methods: To evaluate the utility of cCMVR, we analyzed 389 CMV seropositive patients who had received their first allo‐HCT. cCMVR was defined as the probability of the state where anti‐CMV drugs were administered for CMVR or CMV disease without relapse or death at any time. Results: We compared two groups with or without letermovir prophylaxis (LTV and no‐LTV groups). The 1‐, 2‐, 3‐, and 6‐month cCMVR values were 0.0%, 0.0%, 2.9%, and 2.9% in the LTV group, and 7.1%, 31.9%, 11.0%, and 0.8% in the no‐LTV group. In the LTV group, cCMVR never exceeded 10%, while in the no‐LTV group, cCMVR peaked at approximately 2 months after allo‐HCT, and fewer than 5% of patients developed CMVR after 4 months post‐HCT. Next, in the no‐LTV group, we assessed cCMVR stratified according to the presence of risk factors for the simple cumulative incidence of CMVR, and this revealed that patients grafted from HLA‐mismatched related donors and those who received alemtuzumab for GVHD prophylaxis appeared to experience repeated episodes of CMVR, whereas the early difference in cCMVR according to pretransplant CMV‐IgG titer diminished over time. Conclusion: cCMVR could be a valuable indicator for visualizing recurrent CMV infection and illustrating differences in the time course of CMVR.
- 6 September 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1762-1772
Serum thioredoxin at allogeneic haematopoietic stem cell transplantation predicts acute graft‐versus‐host disease
Summary: Thioredoxin (TXN) is a component of a major reductive system in various eukaryotes. Although oxidative stress is considered to contribute to the development of acute graft‐versus‐host disease (GVHD), the clinical significance of TXN remains to be elucidated. The current study included 118 patients who had undergone their first allogeneic haematopoietic stem cell transplantation (allo‐HSCT) between 2022 and 2025, and their serum samples at day 0 were sequentially collected (training cohort). The study also assessed 47 patients who had undergone their first allo‐HSCT between 2012 and 2015 and whose serum at around day 0 had previously been cryopreserved and was available (validation cohort). The high‐TXN group showed a lower cumulative incidence of grade II–IV acute GVHD (100‐day incidence: 47.5% vs. 59.2%), although the difference did not reach statistical significance ( p = 0.058). The validation cohort demonstrated similar results (0% vs. 35.8%, p = 0.053). However, multivariate analysis revealed that high‐TXN group was significantly associated with a reduced risk of acute GVHD (hazard ratio [HR] 0.48, p = 0.031). In addition, the combination of TXN with clinical factors enhanced the predictive potential for acute GVHD compared with that of clinical factors alone ( p = 0.0039). TXN might be useful for predicting acute GVHD and could contribute to the establishment of a prediction model.
- 6 September 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1762-1772
Serum thioredoxin at allogeneic haematopoietic stem cell transplantation predicts acute graft‐versus‐host disease
Summary: Thioredoxin (TXN) is a component of a major reductive system in various eukaryotes. Although oxidative stress is considered to contribute to the development of acute graft‐versus‐host disease (GVHD), the clinical significance of TXN remains to be elucidated. The current study included 118 patients who had undergone their first allogeneic haematopoietic stem cell transplantation (allo‐HSCT) between 2022 and 2025, and their serum samples at day 0 were sequentially collected (training cohort). The study also assessed 47 patients who had undergone their first allo‐HSCT between 2012 and 2015 and whose serum at around day 0 had previously been cryopreserved and was available (validation cohort). The high‐TXN group showed a lower cumulative incidence of grade II–IV acute GVHD (100‐day incidence: 47.5% vs. 59.2%), although the difference did not reach statistical significance ( p = 0.058). The validation cohort demonstrated similar results (0% vs. 35.8%, p = 0.053). However, multivariate analysis revealed that high‐TXN group was significantly associated with a reduced risk of acute GVHD (hazard ratio [HR] 0.48, p = 0.031). In addition, the combination of TXN with clinical factors enhanced the predictive potential for acute GVHD compared with that of clinical factors alone ( p = 0.0039). TXN might be useful for predicting acute GVHD and could contribute to the establishment of a prediction model.
- 17 May 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (8) , 994.e1-994.e11
Vaccine-Induced Anti-HBs Response is Associated with Protection Against Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Cell Transplantation: A Randomized Trial
- 17 May 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (8) , 994.e1-994.e11
Vaccine-Induced Anti-HBs Response is Associated with Protection Against Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Cell Transplantation: A Randomized Trial
- 8 September 2025
- Published by Wiley in Hematological Oncology
- Vol. 43 (5) , e70136
Prognostic Value of C‐Reactive Protein/Platelet Ratio as a Biomarker Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Malignant Lymphoma
Previous studies have shown that the pre‐transplant C‐reactive protein (CRP)/platelet ratio (CP ratio) is a predictor of survival. The aim of this multicenter retrospective study was to evaluate the clinical significance of CP ratio in patients with malignant lymphoma (ML) who underwent allogeneic hematopoietic stem cell transplantation (alloHCT). The cohort included patients with ML who underwent first alloHCT from 2007 to 2021. CP ratio was defined as CRP [mg/dL]/platelet [104/μL] and evaluated prior to alloHCT. The cutoff value for CP ratio was set at 0.05 based on previous studies. A total of 311 cases were analyzed, of which 134 were mature B cell lymphoma, 177 were T/NK cell lymphoma (including 70 cases of adult T‐cell leukemia/lymphoma), and 17 were Hodgkin's lymphoma. The median age was 53 years (range: 17–69 years). High CP ratio was associated with status of disease, presence of infections, poor performance status at alloHCT, and high transfusion volume received prior to alloHCT. Overall survival (OS) at 2 years according to CP ratio (low vs. high) was 61.1% versus 30.1% (p < 0.001), non‐relapse mortality (NRM) was 21.4% versus 40.7% (p = 0.001), and the relapse rate was 23.7% versus 32.6% (p = 0.061), respectively. In multivariate analysis, the high CP ratio group was associated with poor OS (HR = 2.20, 95% CI: 1.61–3.02, p < 0.001) and higher NRM (HR = 1.90, 95% CI: 1.28–2.81, p = 0.0014). High CP ratio was found to be associated with poor post‐transplant OS and NRM, and was a suitable prognostic biomarker for stratifying the risk of patients with ML who are candidates for alloHCT.
- 8 September 2025
- Published by Wiley in Hematological Oncology
- Vol. 43 (5) , e70136
Prognostic Value of C‐Reactive Protein/Platelet Ratio as a Biomarker Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Malignant Lymphoma
Previous studies have shown that the pre‐transplant C‐reactive protein (CRP)/platelet ratio (CP ratio) is a predictor of survival. The aim of this multicenter retrospective study was to evaluate the clinical significance of CP ratio in patients with malignant lymphoma (ML) who underwent allogeneic hematopoietic stem cell transplantation (alloHCT). The cohort included patients with ML who underwent first alloHCT from 2007 to 2021. CP ratio was defined as CRP [mg/dL]/platelet [104/μL] and evaluated prior to alloHCT. The cutoff value for CP ratio was set at 0.05 based on previous studies. A total of 311 cases were analyzed, of which 134 were mature B cell lymphoma, 177 were T/NK cell lymphoma (including 70 cases of adult T‐cell leukemia/lymphoma), and 17 were Hodgkin's lymphoma. The median age was 53 years (range: 17–69 years). High CP ratio was associated with status of disease, presence of infections, poor performance status at alloHCT, and high transfusion volume received prior to alloHCT. Overall survival (OS) at 2 years according to CP ratio (low vs. high) was 61.1% versus 30.1% (p < 0.001), non‐relapse mortality (NRM) was 21.4% versus 40.7% (p = 0.001), and the relapse rate was 23.7% versus 32.6% (p = 0.061), respectively. In multivariate analysis, the high CP ratio group was associated with poor OS (HR = 2.20, 95% CI: 1.61–3.02, p < 0.001) and higher NRM (HR = 1.90, 95% CI: 1.28–2.81, p = 0.0014). High CP ratio was found to be associated with poor post‐transplant OS and NRM, and was a suitable prognostic biomarker for stratifying the risk of patients with ML who are candidates for alloHCT.
- 5 October 2024
- Published by Elsevier in Cytotherapy
- Vol. 27 (2) , 213-221
Female-to-male allogeneic transplantation affects outcomes differently according to the type of haplo-transplantation
- 5 October 2024
- Published by Elsevier in Cytotherapy
- Vol. 27 (2) , 213-221
Female-to-male allogeneic transplantation affects outcomes differently according to the type of haplo-transplantation
- Open Access
- 14 August 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (16) , 4250-4261
Associations between acute and chronic graft-versus-host disease
Chronic graft-versus-host disease (GVHD) is 1 of the major complications after allogeneic hematopoietic cell transplantation (allo-HCT). Although various risk factors for chronic GVHD have been reported, limited data are available regarding the impact of acute GVHD on chronic GVHD. We examined the association between acute and chronic GVHD using a Japanese registry data set. The landmark point was set at day 100 after allo-HCT, and patients who died or relapsed before the landmark point were excluded. In total, 14 618 and 6135 patients who underwent allo-HCT with bone marrow or peripheral blood (BM/PB) and with umbilical cord blood (UCB), respectively, were analyzed. In the BM/PB cohort, the risk for chronic GVHD that requires systemic steroids increased with each increase in acute GVHD grade from 0 to 2 (grade 0 vs 1 [hazard ratio (HR), 1.32; 95% confidence interval (CI), 1.19-1.46; P < .001]; grade 1 vs 2 [HR, 1.41; 95% CI, 1.28-1.56; P < .001]), but the risk was similar between acute GVHD grade 2 and grade 3 to 4 (HR, 1.02; 95% CI, 0.91-1.15; P = 1.0). These findings were confirmed in the UCB cohort. We further observed that the risk for severe chronic GVHD increased with each increment in the grade of acute GVHD, even between acute GVHD grade 2 and grade 3 to (grade 2 vs 3-4: HR, 1.70; 95% CI, 1.12-2.58; P = .025). In conclusion, the preceding profiles of acute GVHD should help to stratify the risk for chronic GVHD and its severity, which might be useful for the development of risk-adopted preemptive strategies for chronic GVHD.
- 14 August 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (16) , 4250-4261
Open AccessAssociations between acute and chronic graft-versus-host disease
Chronic graft-versus-host disease (GVHD) is 1 of the major complications after allogeneic hematopoietic cell transplantation (allo-HCT). Although various risk factors for chronic GVHD have been reported, limited data are available regarding the impact of acute GVHD on chronic GVHD. We examined the association between acute and chronic GVHD using a Japanese registry data set. The landmark point was set at day 100 after allo-HCT, and patients who died or relapsed before the landmark point were excluded. In total, 14 618 and 6135 patients who underwent allo-HCT with bone marrow or peripheral blood (BM/PB) and with umbilical cord blood (UCB), respectively, were analyzed. In the BM/PB cohort, the risk for chronic GVHD that requires systemic steroids increased with each increase in acute GVHD grade from 0 to 2 (grade 0 vs 1 [hazard ratio (HR), 1.32; 95% confidence interval (CI), 1.19-1.46; P < .001]; grade 1 vs 2 [HR, 1.41; 95% CI, 1.28-1.56; P < .001]), but the risk was similar between acute GVHD grade 2 and grade 3 to 4 (HR, 1.02; 95% CI, 0.91-1.15; P = 1.0). These findings were confirmed in the UCB cohort. We further observed that the risk for severe chronic GVHD increased with each increment in the grade of acute GVHD, even between acute GVHD grade 2 and grade 3 to (grade 2 vs 3-4: HR, 1.70; 95% CI, 1.12-2.58; P = .025). In conclusion, the preceding profiles of acute GVHD should help to stratify the risk for chronic GVHD and its severity, which might be useful for the development of risk-adopted preemptive strategies for chronic GVHD.
- 12 June 2024
- Published by Elsevier in Cytotherapy
- Vol. 26 (11) , 1353-1361
Superiority of BM over PBSC for recipients with pre-transplant lung dysfunction in HLA-matched allogeneic HCT
- 12 June 2024
- Published by Elsevier in Cytotherapy
- Vol. 26 (11) , 1353-1361
Superiority of BM over PBSC for recipients with pre-transplant lung dysfunction in HLA-matched allogeneic HCT